PH12015502278A1 - Novel bispecific binding molecules with antitumoral activity - Google Patents
Novel bispecific binding molecules with antitumoral activityInfo
- Publication number
- PH12015502278A1 PH12015502278A1 PH12015502278A PH12015502278A PH12015502278A1 PH 12015502278 A1 PH12015502278 A1 PH 12015502278A1 PH 12015502278 A PH12015502278 A PH 12015502278A PH 12015502278 A PH12015502278 A PH 12015502278A PH 12015502278 A1 PH12015502278 A1 PH 12015502278A1
- Authority
- PH
- Philippines
- Prior art keywords
- amino acid
- seq
- bispecific binding
- binding molecules
- antitumoral activity
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 101100243022 Mus musculus Pcnt gene Proteins 0.000 abstract 1
- -1 amino acid amino acid Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13164555 | 2013-04-19 | ||
| PCT/EP2014/054390 WO2014170063A1 (en) | 2013-04-19 | 2014-03-06 | Novel bispecific binding molecules with antitumoral activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12015502278A1 true PH12015502278A1 (en) | 2016-02-01 |
Family
ID=48128216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12015502278A PH12015502278A1 (en) | 2013-04-19 | 2015-09-30 | Novel bispecific binding molecules with antitumoral activity |
Country Status (15)
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| BR112014030812B1 (pt) | 2012-06-13 | 2022-11-08 | Incyte Holdings Corporation | Compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr |
| ME03015B (me) | 2013-04-19 | 2018-10-20 | Incyte Holdings Corp | Biciklični heterocikli kao fgfr inhibitori |
| PT3083689T (pt) | 2013-12-17 | 2020-08-27 | Genentech Inc | Anticorpos anti-cd3 e métodos de utilização |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
| JP2018526972A (ja) | 2015-06-16 | 2018-09-20 | ジェネンテック， インコーポレイテッド | 抗ｃｄ３抗体及び使用方法 |
| FI126633B (en) | 2015-07-10 | 2017-03-15 | Next Biomed Therapies Oy | Method for the preparation of a library of derivatives of the SH3 domain of recombinant nephrocystin (NPHP1) |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| JP7784795B2 (ja) | 2016-11-15 | 2025-12-12 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与 |
| US10722589B2 (en) * | 2017-04-03 | 2020-07-28 | Covagen Ag | FGFR3 binding molecules |
| JP2020517659A (ja) * | 2017-04-24 | 2020-06-18 | イクノス サイエンシズ エスエー | Ｅｇｆｒ陽性癌の治療のためのｔ細胞リダイレクト二重特異性抗体 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| WO2019033050A1 (en) * | 2017-08-11 | 2019-02-14 | City Of Hope | BISPECIFIC MOLECULE FOR BINDING TO ANTIGEN |
| US11427826B2 (en) | 2017-08-11 | 2022-08-30 | City of Hopw | RNA aptamers against transferrin receptor (TfR) |
| CN111315773A (zh) * | 2017-09-08 | 2020-06-19 | 马弗里克治疗公司 | 含有Fc区的条件性活化的结合部分 |
| IL317013A (en) | 2017-09-08 | 2025-01-01 | Takeda Pharmaceuticals Co | Binding proteins are activated under limited conditions |
| US20190100587A1 (en) * | 2017-10-02 | 2019-04-04 | Covagen Ag | IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS |
| US20190153096A1 (en) | 2017-10-02 | 2019-05-23 | Covagen Ag | Cd3/cd33 bispecific binding molecules |
| SG11202007390YA (en) | 2018-02-08 | 2020-08-28 | Genentech Inc | Bispecific antigen-binding molecules and methods of use |
| SG11202010636VA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Solid forms of an fgfr inhibitor and processes for preparing the same |
| TW201946630A (zh) | 2018-05-04 | 2019-12-16 | 美商英塞特公司 | Fgfr抑制劑之鹽 |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| AU2020395185A1 (en) | 2019-12-04 | 2022-06-02 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| US20210188990A1 (en) | 2019-12-11 | 2021-06-24 | Cilag Gmbh International | Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof |
| AU2020403145B2 (en) | 2019-12-13 | 2025-06-26 | Genentech, Inc. | Anti-Ly6G6D antibodies and methods of use |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TWI874719B (zh) | 2020-11-04 | 2025-03-01 | 美商建南德克公司 | 用抗cd20/抗cd3雙特異性抗體進行治療之給藥 |
| MX2023005130A (es) | 2020-11-04 | 2023-05-25 | Genentech Inc | Dosis subcutanea de anticuerpos biespecificos anti-cd20/anti-cd3. |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| EP4337330A1 (en) | 2021-05-14 | 2024-03-20 | Genentech, Inc. | Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN119013299A (zh) | 2022-04-13 | 2024-11-22 | 基因泰克公司 | 莫苏尼妥珠单抗的药物组合物及使用方法 |
| US20250295809A1 (en) | 2022-05-13 | 2025-09-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2025221728A2 (en) | 2024-04-15 | 2025-10-23 | Janssen Biotech, Inc. | Ltbr binding molecules and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1892248A1 (en) * | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
| US9376477B2 (en) * | 2009-08-27 | 2016-06-28 | Covagen Ag | IL-17 binding compounds and medical uses thereof |
| WO2011116387A1 (en) * | 2010-03-19 | 2011-09-22 | Tetragenetics, Inc. | Production of aglycosylated monoclonal antibodies in ciliates |
| CN107253992B (zh) * | 2010-05-27 | 2022-03-11 | 根马布股份公司 | 针对her2的单克隆抗体 |
-
2014
- 2014-03-06 HK HK16102370.8A patent/HK1214605A1/zh unknown
- 2014-03-06 SG SG11201508231UA patent/SG11201508231UA/en unknown
- 2014-03-06 CA CA2908988A patent/CA2908988A1/en not_active Abandoned
- 2014-03-06 JP JP2016508054A patent/JP6694808B2/ja not_active Expired - Fee Related
- 2014-03-06 MX MX2015014608A patent/MX2015014608A/es unknown
- 2014-03-06 EP EP14710220.6A patent/EP2986630B1/en active Active
- 2014-03-06 KR KR1020157031680A patent/KR20160002882A/ko not_active Withdrawn
- 2014-03-06 CN CN201480022196.2A patent/CN105189544A/zh active Pending
- 2014-03-06 BR BR112015026143A patent/BR112015026143A2/pt not_active IP Right Cessation
- 2014-03-06 EA EA201592006A patent/EA201592006A1/ru unknown
- 2014-03-06 WO PCT/EP2014/054390 patent/WO2014170063A1/en not_active Ceased
- 2014-03-06 AU AU2014256037A patent/AU2014256037B2/en not_active Ceased
-
2015
- 2015-09-30 PH PH12015502278A patent/PH12015502278A1/en unknown
- 2015-10-16 ZA ZA2015/07752A patent/ZA201507752B/en unknown
- 2015-10-19 CL CL2015003085A patent/CL2015003085A1/es unknown
-
2019
- 2019-01-30 JP JP2019013831A patent/JP2019106997A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2986630A1 (en) | 2016-02-24 |
| JP2016516789A (ja) | 2016-06-09 |
| AU2014256037A1 (en) | 2015-10-29 |
| CN105189544A (zh) | 2015-12-23 |
| JP6694808B2 (ja) | 2020-05-20 |
| KR20160002882A (ko) | 2016-01-08 |
| BR112015026143A2 (pt) | 2017-10-17 |
| SG11201508231UA (en) | 2015-11-27 |
| EP2986630B1 (en) | 2018-08-15 |
| CA2908988A1 (en) | 2014-10-23 |
| CL2015003085A1 (es) | 2016-06-03 |
| WO2014170063A1 (en) | 2014-10-23 |
| EA201592006A1 (ru) | 2016-03-31 |
| ZA201507752B (en) | 2017-03-29 |
| HK1214605A1 (zh) | 2016-07-29 |
| JP2019106997A (ja) | 2019-07-04 |
| AU2014256037B2 (en) | 2017-09-21 |
| MX2015014608A (es) | 2016-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502278A1 (en) | Novel bispecific binding molecules with antitumoral activity | |
| CY1121900T1 (el) | Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2 | |
| MX384984B (es) | Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas. | |
| AU2018264321A1 (en) | Bispecific recombinant protein and use thereof | |
| MX353382B (es) | Moleculas de union polipeptido de larga duracion. | |
| UA106607C2 (uk) | Білки специфічного зв'язування і їх застосування | |
| PH12015501651B1 (en) | Antibody constructs for cdh19 and cd3 | |
| HK1254861A1 (zh) | 抗lag3抗体及其用途 | |
| MX2014005108A (es) | Constructos de polipeptidos y sus usos. | |
| NZ703653A (en) | Anti-fap antibodies and methods of use | |
| MX363136B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX360211B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
| MX359384B (es) | Conjunto mejorado de anticuerpos bisespecificos. | |
| MX374291B (es) | Modulocinas basadas en dominio sushi de interleucina-15 (il-15) y receptor alfa de interleucina-15 (il-15ra). | |
| MX2021000155A (es) | Moleculas de proteina multifuncionales que comprenden decorina y su uso. | |
| MX2022001942A (es) | Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas. | |
| NZ610091A (en) | Antibodies | |
| NZ628625A (en) | Polypeptides binding to human complement c5 | |
| PH12018502451A1 (en) | Brain delivery protein | |
| NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
| MX2021001418A (es) | Produccion de proteinas heteromultimericas usando celulas de mamifero. | |
| MX2016008520A (es) | Anticuerpo bdca-2 antihumano novedoso. | |
| MX2015007421A (es) | Proteinas de tipo espiral enrollada modificadas que tienen propiedades mejoradas. | |
| TN2018000358A1 (en) | Humanized anti-basigin antibodies and the use thereof. |